期刊文献+

重组人乳头瘤病毒双价(16/18型)疫苗免疫原性评价方法的研究 被引量:5

Study on recombinant human papillomavirus(16/18) vaccine immunogenicity evaluation assay
原文传递
导出
摘要 目的:探讨重组人乳头瘤病毒双价(16/18型)候选疫苗免疫原性评价方法。方法:对以假病毒为基础的中和实验(Zs-Green法)测定血清中和滴度,以微球为基础建立的Luminex法测定中和滴度和ELISA法测定抗体滴度的3种方法进行相关性研究以及体内效价测定(ED50法)和体外相对效力测定(IVRP法)的相关性分析,同时对5种免疫原性的评价方法进行重复性验证。结果:ZsGreen法、Luminex法测定的中和滴度和ELISA法测定的抗体滴度检测结果表明:滴度值呈明显的剂量效应以及侯选疫苗具有良好的免疫原性。采用SPSS统计软件分析,对于HPV 16L1 ZsGreen法、Luminex法和ELISA法的相关系数分别为0.791,0.800,0.747(Spearman相关系数)和HPV 18L1的相关系数分别为0.734,0.625,0.634(Spearman相关系数)。并且ED50法和IVRP法具有一定的相关性。5种方法重复性验证的RSD分别为:5.3%(ZsGreen)、5.2%(Luminex)、8.0%(ELISA)、32.3%(ED50)、6.3%(IVRP)。结论:建立的HPV 16和HPV 18型疫苗评价方法为快速准确地评价免疫原性提供了多种解决方法。 Objective:To explore on recombinant human papillomavirus(16/18) candidate vaccine immunogenicity evaluation.Methods:To study the correlation of the ZsGreen neutralizing antibody titer(based on pseudovirus),the average of the HPV-Luminex neutralizing antibody titer(based on beads) and the average of the ELISA antibody titer.And to explore the correlation between potency(ED50) and in vitro relative potency(IVRP).Then we compare the repeatability validation of all five methods.Results:The results of antibody titer by ZsGreen,Luminex and ELISA show the antibody titers have obvious dose-effect relationship and candidate vaccine has good immunogenicity.By SPSS statistical analysis,ZsGreen,Luminex and ELISA correlation coefficient are 0.791,0.800,0.747(Spearman coefficient) for HPV 16L1,correlation coefficient are 0.734,0.625,0.634(Spearman coefficient) for HPV 18L1.ED50 and IVRP have certain relationship.The RSD results of five methods are 5.3%(ZsGreen),5.2%(Luminex),8.0%(ELISA),32.3%(ED50),6.3%(IVRP).Conclusion:Established HPV(16/18) vaccine evaluation assay provides multiple solutions to evaluate vaccine immunogenicity rapidly.
出处 《药物分析杂志》 CAS CSCD 北大核心 2011年第9期1743-1749,共7页 Chinese Journal of Pharmaceutical Analysis
基金 上海市科学技术委员会资助项目(08431901400)
关键词 生物制品 重组疫苗 人乳头瘤病毒 免疫原性 纽扣珊瑚绿色荧光蛋白法(ZsGreen) 液相芯片法(Luminex) 酶联免疫吸附测定(ELISA) 体内效价测定 体外相对效力测定 biologicals recombinant vaccine human papillomavirus(HPV) immunogenicity ZsGreen Luminex enzyme linked immunosorbent assay(ELISA) body titer determination in vitro relative potency(IVRP)
  • 相关文献

参考文献10

  • 1Walboomers JM,Jacobs MV,Manos MM,et al.Human papillomavirus is a necessary cause of invasive cervical cancer world wide.J Pathol,1999,189(1):12.
  • 2Bosch FX,Lorincz A,Munoz N,et al.The causal relation between human papillomavirus and cervical cancer.J Clin Pathol,2002,55(4):244.
  • 3雷建强,沈琼,张高峡.人乳头状瘤假病毒中和抗体滴度和ELISA法测定的小鼠血清抗体滴度的相关性研究[J].中华微生物学和免疫学杂志,2009,29(11):1049-1054. 被引量:7
  • 4卢五迅,程通,李少伟,潘晖榕,沈文通,陈毅歆,张涛,郑舟,张军,夏宁邵.人乳头瘤病毒16型假病毒中和实验的建立和初步应用[J].生物工程学报,2006,22(6):990-995. 被引量:13
  • 5Opalka D,Lachman CE,MacMullen SA,et al.Simultaneous quantitation of types antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6,11,16,and 18 by a multiplexed luminexassay.Clin Diagn Lab Immunol,2003,10(1):108.
  • 6Retzlaff MS,Wang F,Morley T,et al.Correlation between mouse potency and in vitro relative potency for human papillomavirus type 16 virus-like particles and Gardasil vaccine samples.Hum Vaccin,2005,1(5):191.
  • 7Pastrana DV,Buck CB,Pang YY,et al.Reactivity of human sera in a sensitive,high-throughput pseudovirus-based papillomavirus neutralization assay for HPV 16 and HPV 18. Virology,2004,321 (2):205.
  • 8Dias D, Doren JV, Schlottmann S, et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papiUomaviruses 6,11, 16, and 18. Clin Diagn Lab lmrnunol,2005,12 ( 8 ) :959.
  • 9Ferguson M,Heath A,Johnes S,et al. Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses. Int J Cancer, 2006,118 (6) : 1508.
  • 10吴雪伶,王佑春.人乳头瘤病毒中和抗体检测方法的研究进展[J].中国生物制品学杂志,2008,21(7):632-636. 被引量:3

二级参考文献38

  • 1张卉,赵莉,任皎,高见,边涛,范江涛,阮力,陈心秋,田厚文.HPV11型L2E7融合蛋白的原核表达及其免疫效果观察[J].中华实验和临床病毒学杂志,2007,21(2):156-158. 被引量:3
  • 2F 奥斯伯 R布伦特 等.精编分子生物学实验指南[M].北京:科学出版社,1998.312-328.
  • 3Kirnbauer R, Hubbert NL, Wheeler CM, et al. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. Natl Cancer Inst, 1994, 86 (7):494-499.
  • 4Christensen ND, Dillner J, Eklund C, et al. Surface conformational and linear epitopes on HPV-16 and HPV-18 L1 virus-like particles as defined by monoclonal antibodies. Virology, 1996, 223(1) : 174-184.
  • 5Combita AL, Touze A, Bousarghin L, et al. Identification of two cross-neutralizing linear epitopes within the L! major capsid protein of human papillomaviruses. J Virol, 2002, 76 ( 13 ) : 6480- 6486.
  • 6Giroglou T, Sapp M, Lane C, et al. Immunological analyses of human papillomavirus capsids. Vaccine, 2001, 19 ( 13-14 ) : 1783-1793.
  • 7Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer world- wide. J Pathol, 1999, 189(1): 12-19.
  • 8Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiological evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Nat Cancer Inst, 1993, 85 (12) : 958-964.
  • 9Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nature Rev, 2004, 4 ( 1 ) : 46-54.
  • 10Kirnbauer R, Taub J, Greenstone H, et al. Efficient self-assembly of human papillomavirus type 16 L1 and L1-L2 into virus-like particles. J Virol, 1993, 67(12) : 6929-6936.

共引文献19

同被引文献32

  • 1Walboomers JM,Jacobs MV,Manos MM,et al.Human papillomavirus is a necessary cause of invasive cervical cancer world wide.J Pathol,1999,189(1):12.
  • 2Bosch FX,Lorincz A,Munoz N,et al.The causal relation between human papillomavirus and cervical cancer.J Clin Pathol,2002,55(4):244.
  • 3Baker TS,Newcomb WW,Olson NH,et al.Structures of bovine and human papillomaviruses analysis by cryoelectron microscopy and three dimensional image reconstruction.Biophy J, 1991,60(6):1445.
  • 4Belnap DM,Olson NH,Cladel NM,et al. Conserved features in papillomavirus and polyomavirus capsides J Mol Biol, 1996,259(2):249.
  • 5Li M,Beard P,Estes PA, et al. Intercapsomeric disulfide bonds in papillomavirus assembly and disassembly. J Virol, 1998,72(3):2160.
  • 6McCarthy MP,White WI,Palmer-Hill F, et al. Quantitative disassembly and reassembly of human papillomavirus type 11 viruslike particles in vitro.J Virol, 1998,72(1):32.
  • 7Kim SN,Jeong HS,Park SN,et al. Purification and immunogenicity study of human papillomavirus type 16 L1 protein in Saccharomyces cerevisiae.J Virol Methods,2007,139(1):24.
  • 8Brown DR,Fife KH,Wheeler CM,et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine.Vaccine,2004,22(21-22):2936.
  • 9Harper DM,Franco EL,Wheeler C,et al.Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women:a randomised controlled trial. Lancet,2004,364(9447):1757.
  • 10Lim HK,Linh PT,Hong CH,et al. Enantioselective determination of metoprolol and major metabolites in human urine by capillary electrophoresis. J Chromatogr B,2001,755(1-2):259.

二级引证文献16

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部